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503Abstracts
esomeprazole (EAC) results in direct medical cost savings
compared with 1-week triple therapy (OAC) followed 
by three weeks omeprazole monotherapy, while offering
comparable effectiveness.
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OBJECTIVES: In the assessment of NSAID related GI
events, many authors focus on severe events leading to
hospitalisation. This study aimed at describing medical
practice, resource utilisation and costs of different GI
events related to chronic NSAID use in osteo-arthritis
(OA) and rheumatoid arthritis (RA) patients in Belgium.
METHODS: A random sample of 231 OA and RA
patients with GI events associated with NSAID use was
included in a multicenter GP level chart review. Charts
were assessed by the GP and monitored by an indepen-
dent researcher for all medical resource use related to the
event. Direct medical costs were calculated by multiply-
ing resource use with standard costs for the health insur-
ance. GI events were categorised as GI discomfort (=
minor event), symptomatic ulcer, anaemia with occult
bleeding and severe (i.e. hospitalised) gastro-intestinal
pathologies. RESULTS: Thirty-ﬁve patients (15.2%) were
RA patients, 196 (84.8%) OA. The average age of the
sample was 61.0y (st.dev 14.7y). 45% were male. The
median duration of a GI event was 10 days, the average
was 23 days. The average cost per patient was €284. The
cost per type of event (in €) was as follows (p < 0.001
Kruskal Wallis): GI Discomfort (n = 155): 198 (SE = 41);
Ulcer (n = 66): 364 (SE = 28); Anaemia (n = 7): 756 (SE
= 234); Severe GI (n = 3): 1,896 (SE = 1,585). Total cost
(n x mean) was: GI Discomfort: 30,657 (46.7%); Ulcer:
24,020 (36.6%); Anaemia: 5,293 (8.1%); Severe GI:
5,688 (8.7%). It was thus shown that GI discomfort, due
to the relative high number of patients, leads to 47% of
total GI related costs. CONCLUSIONS: Many patients
with minor NSAID related GI events visit a physician.
The resulting use of healthcare resources to manage these
events should be taken into account in economic evalua-
tions of measures to prevent GI events.
GASTROINTESTINAL DISEASES/DISORDERS—
Clinical Outcomes
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OBJECTIVE: Two studies have reported results compar-
ing esomeprazole 40mg and lansoprazole 30mg in the
healing of reﬂux oesophagitis. The two studies come to
different conclusions. One study shows superiority for
esomeprazole at four and eight weeks while the other
claims equivalence. The aim of this work was to combine
the results of the 2 studies by meta-analysis to ascertain
if there is a difference in healing rates with esomeprazole
40mg and lansoprazole 30mg. METHODS: Meta-
analysis of intention-to-treat (ITT) endoscopic healing
rates at four and eight weeks. If the healing rates were
not presented in an ITT format they were recalculated.
ITT was deﬁned as “patients being analysed in the treat-
ment arm that they entered at randomisation, regardless
of whether they dropped-out, received the incorrect
treatment or withdrew before completion of the trial”.
RESULTS: At 4 weeks, esomeprazole 40mg is signiﬁ-
cantly more effective than lansoprazole 30mg in the
healing of reﬂux oesophagitis (Relative Risk 1.05; 95%
CI 1.02–1.09). Similarly, at 8 weeks esomeprazole 40mg
is signiﬁcantly more effective than lansoprazole 30mg
(Relative Risk 1.04; 95% CI 1.01–1.06). A chi-squared
test was carried out to investigate possible heterogeneity.
Signiﬁcant heterogeneity was not detected at four or eight
weeks. CONCLUSIONS: Esomeprazole 40mg is signiﬁ-
cantly more effective than lansoprazole 30mg in the
healing of reﬂux oesophagitis at 4 and 8 weeks.
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OBJECTIVE: To analyze the safety, effectiveness and cost
savings of rabeprazole at the McGuire Veterans Affairs
Medical Center. Similar effectiveness and safety pro-
ﬁles among the proton pump inhibitors (PPI) prompted 
a dose-per-dose interchange (1 :1) of rabeprazole with 
currently prescribed PPIs (lansoprazole and omeprazole)
when rabeprazole was added to the VA National Formu-
lary priced 75%–80% less than its competitors. Rabepra-
zole was also identiﬁed as drug-of-choice for future use
in PPI-naïve patients. METHODS: Patients with active
rabeprazole prescriptions (N = 3885) and those failing
therapy (N = 249) as of 5/22/02 were selected for analy-
sis (total N = 4134). Patients were divided into two
subsets: those participating in the PPI therapeutic inter-
change: N = 2088; and PPI-naïve patients prescribed
rabeprazole after formulary addition: N = 1797. A retro-
spective database analysis of 14,565 PPI prescriptions
from January 1, 2000–May 22, 2002 was conducted to
assess PPI prescribing trends, pharmacy acquisition costs,
tolerance, effectiveness and dose creep for these individ-
uals. RESULTS: Safety: Patients experience an adverse
drug event (ADE): N = 65 (1.6%). Effectiveness: Patients
failing rabeprazole: N = 184 (4.5%). Total number 
